Considering patients with success and refractory to RAI therapy, both groups did not differ according to age, gender, previous duration or type of ATD treatment, smoking habits, TPO-Ab, or thyroglobulin antibody levels before RAI treatment (P > .05) (Table 2). This evidence concerns the gene TG and Jeune syndrome.